106 related articles for article (PubMed ID: 18570182)
1. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.
Ranheim T; Mattingsdal M; Lindvall JM; Holla OL; Berge KE; Kulseth MA; Leren TP
J Cell Physiol; 2008 Nov; 217(2):459-67. PubMed ID: 18570182
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
[TBL] [Abstract][Full Text] [Related]
3. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.
Herbert B; Patel D; Waddington SN; Eden ER; McAleenan A; Sun XM; Soutar AK
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1333-9. PubMed ID: 20448210
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
6. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
[TBL] [Abstract][Full Text] [Related]
7. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
[TBL] [Abstract][Full Text] [Related]
8. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
[TBL] [Abstract][Full Text] [Related]
9. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
[TBL] [Abstract][Full Text] [Related]
10. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
11. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
12.
Huang L; Cheng Y; Mu Y; Li K
Anal Cell Pathol (Amst); 2023; 2023():6985808. PubMed ID: 36655117
[TBL] [Abstract][Full Text] [Related]
13. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9
Lammi C; Bollati C; Lecca D; Abbracchio MP; Arnoldi A
Nutrients; 2019 Jul; 11(7):. PubMed ID: 31330826
[TBL] [Abstract][Full Text] [Related]
14. Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes.
Kourimate S; Chétiveaux M; Jarnoux AL; Lalanne F; Costet P
Atherosclerosis; 2009 Sep; 206(1):134-40. PubMed ID: 19269636
[TBL] [Abstract][Full Text] [Related]
15. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
Levy E; Ben Djoudi Ouadda A; Spahis S; Sane AT; Garofalo C; Grenier É; Emonnot L; Yara S; Couture P; Beaulieu JF; Ménard D; Seidah NG; Elchebly M
Atherosclerosis; 2013 Apr; 227(2):297-306. PubMed ID: 23422832
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
Leren TP
Clin Genet; 2004 May; 65(5):419-22. PubMed ID: 15099351
[TBL] [Abstract][Full Text] [Related]
20. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
